APP and Alzheimer disease: Regardless, compounds that can dramatically increase ABCC1 transport activity or those that can increase ABCC1 expression may prove to be viable drugs for the treatment or prevention of AD by not only increasing clearance of Abeta from the brain, but also by reducing the amount of Abeta that is produced.